Literature DB >> 21040724

Optimization of endochin-like quinolones for antimalarial activity.

Rolf Winter1, Jane X Kelly, Martin J Smilkstein, David Hinrichs, Dennis R Koop, Michael K Riscoe.   

Abstract

Our prior work on tricyclic acridones combined with a desire to minimize the tricyclic system led to an interest in antimalarial quinolones and a reexamination of endochin, an experimental antimalarial from the 1940's. In the present article, we show that endochin is unstable in the presence of murine, rat, and human microsomes which may explain its relatively poor antimalarial activity in mammalian systems. We also profile the structure-activity relationships of ≈ 30 endochin-like quinolone (ELQ) analogs and highlight features that are associated with enhanced metabolic stability, potent antiplasmodial activity against multidrug resistant strains of Plasmodium falciparum, and equal activity against an atovaquone-resistant clinical isolate. Our work also features an ELQ construct containing a polyethylene glycol carbonate pro-moiety that is highly efficacious by oral administration in a murine malaria model. These findings provide compelling evidence that development of ELQ therapeutics is feasible. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21040724      PMCID: PMC3025093          DOI: 10.1016/j.exppara.2010.10.016

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  9 in total

1.  Comparison of efficacies of cysteine protease inhibitors against five strains of Plasmodium falciparum.

Authors:  A Singh; P J Rosenthal
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

2.  Some 3-alkyl-2,4-quinolinediols.

Authors:  R H BAKER; G R LAPPIN; B RIEGEL
Journal:  J Am Chem Soc       Date:  1946-07       Impact factor: 15.419

3.  [Not Available].

Authors:  W KIKUTH; L MUDROW-REICHENOW
Journal:  Z Hyg Infektionskr       Date:  1947-01-06

4.  Reduced in-vitro susceptibility to mefloquine in West African isolates of Plasmodium falciparum.

Authors:  A M Oduola; W K Milhous; L A Salako; O Walker; R E Desjardins
Journal:  Lancet       Date:  1987-12-05       Impact factor: 79.321

5.  Evaluation and lead optimization of anti-malarial acridones.

Authors:  Rolf W Winter; Jane X Kelly; Martin J Smilkstein; Rozalia Dodean; Grover C Bagby; R Keaney Rathbun; Joshua I Levin; David Hinrichs; Michael K Riscoe
Journal:  Exp Parasitol       Date:  2006-07-07       Impact factor: 2.011

6.  Plasmodium falciparum: the effects of atovaquone resistance on respiration.

Authors:  E Suswam; D Kyle; N Lang-Unnasch
Journal:  Exp Parasitol       Date:  2001-08       Impact factor: 2.011

7.  Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening.

Authors:  Martin Smilkstein; Nongluk Sriwilaijaroen; Jane Xu Kelly; Prapon Wilairat; Michael Riscoe
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

8.  Human malaria parasites in continuous culture.

Authors:  W Trager; J B Jensen
Journal:  Science       Date:  1976-08-20       Impact factor: 47.728

9.  Antimalarial quinolones: synthesis, potency, and mechanistic studies.

Authors:  Rolf W Winter; Jane X Kelly; Martin J Smilkstein; Rozalia Dodean; David Hinrichs; Michael K Riscoe
Journal:  Exp Parasitol       Date:  2007-11-07       Impact factor: 2.011

  9 in total
  34 in total

1.  Targeted Structure-Activity Analysis of Endochin-like Quinolones Reveals Potent Qi and Qo Site Inhibitors of Toxoplasma gondii and Plasmodium falciparum Cytochrome bc1 and Identifies ELQ-400 as a Remarkably Effective Compound against Acute Experimental Toxoplasmosis.

Authors:  Erin V McConnell; Igor Bruzual; Sovitj Pou; Rolf Winter; Rozalia A Dodean; Martin J Smilkstein; Alina Krollenbrock; Aaron Nilsen; Lev N Zakharov; Michael K Riscoe; J Stone Doggett
Journal:  ACS Infect Dis       Date:  2018-08-30       Impact factor: 5.084

2.  4(1H)-Quinolones with liver stage activity against Plasmodium berghei.

Authors:  Alexis N Lacrue; Fabián E Sáenz; R Matthew Cross; Kenneth O Udenze; Andrii Monastyrskyi; Steven Stein; Tina S Mutka; Roman Manetsch; Dennis E Kyle
Journal:  Antimicrob Agents Chemother       Date:  2012-11-05       Impact factor: 5.191

3.  4(1H)-pyridone and 4(1H)-quinolone derivatives as antimalarials with erythrocytic, exoerythrocytic, and transmission blocking activities.

Authors:  Andrii Monastyrskyi; Dennis E Kyle; Roman Manetsch
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

4.  Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials.

Authors:  Yiqun Zhang; Julie A Clark; Michele C Connelly; Fangyi Zhu; Jaeki Min; W Armand Guiguemde; Anupam Pradhan; Lalitha Iyer; Anna Furimsky; Jason Gow; Toufan Parman; Farah El Mazouni; Margaret A Phillips; Dennis E Kyle; Jon Mirsalis; R Kiplin Guy
Journal:  J Med Chem       Date:  2012-04-18       Impact factor: 7.446

5.  Improving solubility and oral bioavailability of a novel antimalarial prodrug: comparing spray-dried dispersions with self-emulsifying drug delivery systems.

Authors:  Suresh Potharaju; Shravan Kumar Mutyam; Mingtao Liu; Carol Green; Lisa Frueh; Aaron Nilsen; Sovitj Pou; Rolf Winter; Michael K Riscoe; Gita Shankar
Journal:  Pharm Dev Technol       Date:  2020-02-12       Impact factor: 3.133

6.  ELQ-300 prodrugs for enhanced delivery and single-dose cure of malaria.

Authors:  Galen P Miley; Sovitj Pou; Rolf Winter; Aaron Nilsen; Yuexin Li; Jane X Kelly; Allison M Stickles; Michael W Mather; Isaac P Forquer; April M Pershing; Karen White; David Shackleford; Jessica Saunders; Gong Chen; Li-Min Ting; Kami Kim; Lev N Zakharov; Cristina Donini; Jeremy N Burrows; Akhil B Vaidya; Susan A Charman; Michael K Riscoe
Journal:  Antimicrob Agents Chemother       Date:  2015-06-29       Impact factor: 5.191

7.  Endochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosis.

Authors:  J Stone Doggett; Aaron Nilsen; Isaac Forquer; Keith W Wegmann; Lorraine Jones-Brando; Robert H Yolken; Claudia Bordón; Susan A Charman; Kasiram Katneni; Tracey Schultz; Jeremy N Burrows; David J Hinrichs; Brigitte Meunier; Vern B Carruthers; Michael K Riscoe
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-10       Impact factor: 11.205

8.  Design and Synthesis of Orally Bioavailable Piperazine Substituted 4(1H)-Quinolones with Potent Antimalarial Activity: Structure-Activity and Structure-Property Relationship Studies.

Authors:  Raghupathi Neelarapu; Jordany R Maignan; Cynthia L Lichorowic; Andrii Monastyrskyi; Tina S Mutka; Alexis N LaCrue; Lynn D Blake; Debora Casandra; Sherwin Mashkouri; Jeremy N Burrows; Paul A Willis; Dennis E Kyle; Roman Manetsch
Journal:  J Med Chem       Date:  2018-02-09       Impact factor: 7.446

9.  Inhibition of cytochrome bc1 as a strategy for single-dose, multi-stage antimalarial therapy.

Authors:  Allison M Stickles; Li-Min Ting; Joanne M Morrisey; Yuexin Li; Michael W Mather; Erin Meermeier; April M Pershing; Isaac P Forquer; Galen P Miley; Sovitj Pou; Rolf W Winter; David J Hinrichs; Jane X Kelly; Kami Kim; Akhil B Vaidya; Michael K Riscoe; Aaron Nilsen
Journal:  Am J Trop Med Hyg       Date:  2015-04-27       Impact factor: 2.345

Review 10.  Antimalarial drug discovery - approaches and progress towards new medicines.

Authors:  Erika L Flannery; Arnab K Chatterjee; Elizabeth A Winzeler
Journal:  Nat Rev Microbiol       Date:  2013-11-11       Impact factor: 60.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.